EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Long‐term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha‐mannosidosis: A phase 2, open label, multicenter study

Nathalie Guffon iD, Vassiliki Konstantopoulou, Julia B Hennermann, Nicole Muschol, Irene Bruno, Albina Tummolo, Ferdinando Ceravolo, Giulia Zardi, Andrea Ballabeni, Allan Lund

Journal of Inherited Metabolic Disease · 2023-07 · 46 (4) · 705-719

DOI: 10.1002/jimd.12602 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 13.03.2023. Verfasst von Nathalie Guffon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Reference Centre of Inherited Metabolic Diseases, CERLYMM, HCL, Lyon, France. Hauptthemen laut MEDLINE: alpha-Mannosidosis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alpha‐mannosidosis (AM) is a rare, autosomal recessive, lysosomal storage disorder caused by alpha‐mannosidase deficiency that leads to the accumulation of mannose‐rich oligosaccharides. AM symptoms and severity vary among individuals; consequently, AM is often not diagnosed until late childhood. Velmanase alfa (VA), a recombinant human lysosomal alpha‐mannosidase product, is the first enzyme replacement therapy indicated to treat non‐neurological symptoms of AM in Europe. Previous studies suggested that early VA treatment in children may produce greater clinical benefit over the disease course than starting treatment in adolescents or adults; however, long‐term studies in children are limited, and very few studies include children under 6 years of age. The present phase 2, multicenter, open‐label study evaluated the safety and efficacy of long‐term VA treatment in children under 6 years of age with AM. Five children (three males) received VA weekly for ≥24 months, and all children completed the study. Four children experienced adverse drug reactions (16 events) and two experienced infusion‐related reactions (12 events). Most (99.5%) adverse events were mild or moderate, and none caused study discontinuation. Four children developed antidrug antibodies (three were neutralizing). After VA treatment, all children improved in one or more efficacy assessments of serum oligosaccharide concentrations (decreases), hearing, immunological profile, and quality of life, suggesting a beneficial effect of early treatment. Although the small study size limits conclusions, these results suggest that long‐term VA treatment has an acceptable safety profile, is well tolerated, and may provide potential benefits to patients with AM under 6 years of age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-MannosidosisMaleAdultAdolescentHumansChildChild, PreschoolQuality of Lifealpha-MannosidaseLysosomesAntibodies

Stichwörter der Autor:innen

alpha-mannosidosisantidrug antibodyenduranceoligosaccharidespharmacokineticsphysical functioningvelmanase alfa

Substanzen

alpha-MannosidaseAntibodies

Autor:innen und Institutionen

  • Reference Centre of Inherited Metabolic Diseases, CERLYMM, HCL, Lyon, France.
  • Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Center for Pediatric and Adolescent Medicine, Villa Metabolica, University Medical Center Mainz, Mainz, Germany.
  • Department of Pediatrics, International Center for Lysosomal Disorders (ICLD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste, Italy.
  • Department of Metabolic Diseases and Clinical Genetics, Bari, Italy.

ORCID-Profile: Nathalie Guffon

Zitieren

APA

Guffon, N., Konstantopoulou, V., Hennermann, J. B., Muschol, N., Bruno, I., Tummolo, A., Ceravolo, F., Zardi, G., Ballabeni, A., & Lund, A. (2023). Long‐term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha‐mannosidosis: A phase 2, open label, multicenter study. Journal of Inherited Metabolic Disease, 46(4), 705-719. https://doi.org/10.1002/jimd.12602

Vancouver

Guffon N, Konstantopoulou V, Hennermann JB, Muschol N, Bruno I, Tummolo A, et al. Long‐term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha‐mannosidosis: A phase 2, open label, multicenter study. Journal of Inherited Metabolic Disease. 2023;46(4):705-719. doi:10.1002/jimd.12602

BibTeX
@article{Guffon2023,
  author = {Guffon, Nathalie and Konstantopoulou, Vassiliki and Hennermann, Julia B and Muschol, Nicole and Bruno, Irene and Tummolo, Albina and Ceravolo, Ferdinando and Zardi, Giulia and Ballabeni, Andrea and Lund, Allan},
  title = {Long‐term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha‐mannosidosis: A phase 2, open label, multicenter study},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2023},
  volume = {46},
  number = {4},
  pages = {705--719},
  doi = {10.1002/jimd.12602}
}
Kostenlos starten →